
Brooks Laboratories Downgraded to Strong Sell Amidst Expensive Valuation and Weak Financials
2026-11-16 08:11:04Brooks Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMojo as of 13 Nov 2026, reflecting a deteriorating outlook driven primarily by an expensive valuation, stagnant financial trends, weak quality metrics, and unfavourable technical indicators. The pharmaceutical company’s micro-cap status and recent quarterly results have further compounded investor concerns, signalling caution for stakeholders.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-10-28 10:10:44Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 August 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 28 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-10-17 10:10:44Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 August 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 17 October 2026, providing investors with the latest insights into its performance and prospects.
Read More
Brooks Laboratories Ltd Locks at Upper Circuit With 20% Gain — Buyers Queue, Sellers Absent
2026-10-08 11:00:08At Rs 70.53, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 19.99% on 08 Oct 2026, with buyers queuing and no sellers willing to part with shares.
Read More
Brooks Laboratories Ltd Locks at Upper Circuit With 9.99% Gain — Buyers Queue, Sellers Absent
2026-10-06 11:00:09At Rs 59.66, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 9.99% on 6 Oct 2026, with buyers queuing and no sellers willing to part with shares.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-10-06 10:10:36Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-09-25 10:10:42Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-09-14 10:10:46Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
2026-09-02 10:11:11Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 September 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Credit Rating
12-Nov-2026 | Source : BSEIntimation of upgrade in Credit Rating
Announcement under Regulation 30 (LODR)-Newspaper Publication
09-Nov-2026 | Source : BSEBrooks Laboratories Limited has informed the exchange about copy of Newspaper Publication.
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2026
07-Nov-2026 | Source : BSEFinancial Results for the quarter and half year ended September 30 2026
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Brooks Laboratories Ltd has announced 1:16 rights issue, ex-date: 28 Jul 23